Merck & Co. (MRK)
(Delayed Data from NYSE)
$113.69 USD
+0.60 (0.53%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $113.60 -0.09 (-0.08%) 7:28 PM ET
4-Sell of 5 4
C Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$113.69 USD
+0.60 (0.53%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $113.60 -0.09 (-0.08%) 7:28 PM ET
4-Sell of 5 4
C Value C Growth B Momentum B VGM
Zacks News
The Zacks Analyst Blog Highlights: Apple, NIKE, Walt Disney, PG and MRK
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, NIKE, Walt Disney, PG and MRK
5 Sectors Set to Boom on Coronavirus Vaccine Optimism: Top Picks
by Sweta Killa
While the prospect of a COVID-19 treatment will lead to broad-based gains, some investing areas are expected to benefit the most.
Merck's Keytruda Gets Approval for Esophageal Cancer in Japan
by Zacks Equity Research
Merck's (MRK) Keytruda receives approval in Japan as second-line treatment for esophageal squamous cell carcinoma. A new dosing regimen also receives approval in the country.
Dow Reclaims 28,000: 5 Stocks Driving the ETF Rally
by Sweta Killa
The Dow Jones Industrial Index ended above 28,000 for the first time in six months.
Pharma Stock Roundup: SNY, JNJ Acquisition Deals, FDA Approvals
by Kinjel Shah
J&J (JNJ) proposes to buy Momenta Pharmaceuticals while Sanofi (SNY) offers to buy Principia Biopharma
Merck's Keytruda Positive in First-Line Esophageal Cancer Study
by Zacks Equity Research
Merck's (MRK) Keytruda improves overall survival and progression-free survival compared to current standard of care in first-line metastatic esophageal cancer patients.
Alkermes Starts Phase II Study on ALKS 4230 for Solid Tumors
by Zacks Equity Research
Alkermes (ALKS) initiates phase II ARTISTRY-3 study to evaluate the clinical and immunologic effects of ALKS 4230 monotherapy in patients with advanced solid tumors.
AstraZeneca's Imfinzi Gets Priority Tag for 4-Week Dosing
by Zacks Equity Research
The FDA grants priority review to AstraZeneca's (AZN) sBLA seeking approval of Imfinzi for a four-week fixed-dose regimen for its approved indications in bladder cancer and non-small cell lung cancer.
Bristol Myers & Dragonfly Team Up for Immunotherapy Program
by Zacks Equity Research
Bristol Myers (BMY) collaborates with Dragonfly Therapeutics, Inc. for its experimental immunotherapy program.
Pharma Stock Roundup: FDA Approval for Roche's SMA Drug & Other Updates
by Kinjel Shah
Teaser: FDA approves Roche's (RHHBY) new SMA drug, Evrysdi (risdiplam).
Large-Cap Pharma Industry Outlook Dull Amid Coronavirus Woes
by Kinjel Shah
The Zacks Large-Cap Pharmaceuticals industry ranks in the bottom 26% of more than 250 Zacks industries.
Esperion (ESPR) Q2 Earnings Top, Drug Sales Hurt by Coronavirus
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports mixed second-quarter results as it beats estimates for earnings and misses for sales.
Iovance (IOVA) Q2 Earnings Beat Estimates, Pipeline in Focus
by Zacks Equity Research
Iovance's (IOVA) second-quarter bottom line beats estimates. The company is progressing well with its lead pipeline candidates.
Pharma ETFs Soar on Robust Q2 Earnings
by Sweta Killa
Total earnings of 66.4% of the healthcare market capitalization that has reported so far are up 4.4% on revenue growth of 4%.
Nektar's (NKTR) Q2 Earnings Beat, Bempeg Makes Progress
by Zacks Equity Research
Nektar (NKTR) reports encouraging second-quarter 2020 results. The company continues to progress with its pipeline candidates.
Pharma Stock Roundup: ABBV, MRK Q2 Earnings & Coronavirus Updates in Focus
by Kinjel Shah
Sanofi (SNY)/Glaxo (GSK) and J&J (JNJ) sign deals with U.S. government for coronavirus vaccine candidate. Several drugmakers announce second-quarter results.
Exelixis' (EXEL) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Exelixis (EXEL) beats on earnings and sales in the second quarter.
Novo Nordisk's (NVO) Q2 Earnings Beat Estimates, Sales Miss
by Zacks Equity Research
Novo Nordisk's (NVO) earnings surpass estimates but revenues miss the same in the second quarter of 2020.
Moderna (MRNA) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Moderna (MRNA) reports narrower-than-expected second-quarter loss. Shares decline presumably on absence of any new data on coronavirus vaccine candidate.
Bristol-Myers (BMY) Q2 Earnings Beat, 2020 Earnings View Up
by Zacks Equity Research
Bristol-Myers (BMY) beats on earnings and sales in the second quarter on the strength of Revlimid and Eliquis.
Corcept (CORT) Q2 Earnings Top Estimates, Revenues Miss Mark
by Zacks Equity Research
Corcept's (CORT) earnings trump estimates for the second quarter of 2020 while revenues fall shy of the same.
Epizyme's (EPZM) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Epizyme (EPZM) reports a wider-than-expected loss and misses sales estimates in the second quarter of 2020.
3 Diverse Large-Cap Stocks to Buy Now to Boost Your Long-Term Portfolio
by Benjamin Rains
Investors should consider adding a few large-cap names that are prepared to grow for years to come. These three stocks also pay dividends and provide exposure to three very different and vital industries...
5 Growth ETFs & Stocks to Ride the Market Rally
by Sweta Killa
Growth investing has taken the lead over value and is likely to stay given a slew of reasons.
Will Eliquis, Revlimid Drive Bristol-Myers (BMY) Q2 Earnings?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports second-quarter 2020 results.